Nuvation Bio Inc. Operating Cash Flow
Nuvation Bio Inc. (NUVB) reported Operating Cash Flow of -$37.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Nuvation Bio Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$42.97M.
- Nuvation Bio Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $5.07M.
- Nuvation Bio Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$29.73M.
- Nuvation Bio Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$52.89M.
- Nuvation Bio Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$173.43M.
- Nuvation Bio Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$130.41M.
- Nuvation Bio Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$68.00M.
- Nuvation Bio Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$96.11M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 5 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 8 month | Net Cash Provided by (Used in) Operating Activities 8 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$42.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$37.90M 10-Q · filed 2026-08-06 | -$67.63M derived: sum of 3 quarters · filed 2026-08-06 | -$120.52M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $5.07M 10-Q · filed 2026-05-04 | -$24.66M derived: sum of 2 quarters · filed 2026-05-04 | -$77.55M derived: sum of 3 quarters · filed 2026-05-04 | -$125.73M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$29.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$82.62M derived: sum of 2 quarters · filed 2026-03-02 | -$130.80M derived: sum of 3 quarters · filed 2026-08-06 | -$173.43M 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | -$52.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$101.07M derived: sum of 2 quarters · filed 2026-08-06 | -$143.69M 10-Q · filed 2025-11-03 | -$190.00M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$48.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$90.81M 10-Q · filed 2026-08-06 | -$137.11M derived: sum of 3 quarters · filed 2026-08-06 | -$168.19M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$42.63M 10-Q · filed 2026-05-04 | -$88.93M derived: sum of 2 quarters · filed 2026-05-04 | -$120.01M derived: sum of 3 quarters · filed 2026-05-04 | -$157.34M derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | -$46.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$77.39M derived: sum of 2 quarters · filed 2026-03-02 | -$114.71M derived: sum of 3 quarters · filed 2026-03-02 | -$130.41M 10-K · filed 2026-03-02 | ||||
| 2024-09-30 | -$31.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$68.41M derived: sum of 2 quarters · filed 2025-11-03 | -$84.11M 10-Q · filed 2025-11-03 | -$99.14M derived: sum of 4 quarters · filed 2025-11-03 | ||||
| 2024-06-30 | -$37.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$53.03M 10-Q · filed 2025-08-07 | -$68.06M derived: sum of 3 quarters · filed 2025-08-07 | -$84.21M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$15.70M 10-Q · filed 2025-05-07 | -$30.73M derived: sum of 2 quarters · filed 2025-05-07 | -$46.89M derived: sum of 3 quarters · filed 2025-05-07 | -$64.37M derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | -$15.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$31.18M derived: sum of 2 quarters · filed 2025-03-06 | -$48.67M derived: sum of 3 quarters · filed 2025-03-06 | -$68.00M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | -$16.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$33.64M derived: sum of 2 quarters · filed 2024-11-06 | -$52.97M 10-Q · filed 2024-11-06 | -$69.14M derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | -$17.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$36.81M 10-Q · filed 2024-08-05 | -$52.98M derived: sum of 3 quarters · filed 2024-08-05 | -$81.08M derived: sum of 4 quarters · filed 2024-08-05 | ||||
| 2023-03-31 | -$19.33M 10-Q · filed 2024-05-14 | -$35.50M derived: sum of 2 quarters · filed 2024-05-14 | -$63.59M derived: sum of 3 quarters · filed 2024-05-14 | -$90.51M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | -$16.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$44.26M derived: sum of 2 quarters · filed 2024-02-29 | -$71.18M derived: sum of 3 quarters · filed 2024-02-29 | -$96.11M 10-K · filed 2024-02-29 | ||||
| 2022-09-30 | -$28.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$55.01M derived: sum of 2 quarters · filed 2023-11-02 | -$79.94M 10-Q · filed 2023-11-02 | -$103.42M derived: sum of 4 quarters · filed 2023-11-02 | ||||
| 2022-06-30 | -$26.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$51.85M 10-Q · filed 2023-08-03 | -$75.33M derived: sum of 3 quarters · filed 2023-08-03 | -$88.48M derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | -$24.93M 10-Q · filed 2023-05-04 | -$48.41M derived: sum of 2 quarters · filed 2023-05-04 | -$61.56M derived: sum of 3 quarters · filed 2023-05-04 | -$78.39M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | -$23.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$36.63M derived: sum of 2 quarters · filed 2023-03-15 | -$53.46M derived: sum of 3 quarters · filed 2023-03-15 | -$68.19M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | -$13.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$29.98M derived: sum of 2 quarters · filed 2022-11-03 | -$44.71M 10-Q · filed 2022-11-03 | -$57.65M derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | -$16.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$31.56M 10-Q · filed 2022-08-04 | -$44.50M derived: sum of 3 quarters · filed 2022-08-04 | -$52.53M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | -$14.73M 10-Q · filed 2022-05-09 | $14.73M 10-Q · filed 2021-05-17 | -$27.67M derived: sum of 2 quarters · filed 2022-05-09 | -$35.70M derived: sum of 3 quarters · filed 2022-05-09 | -$59.98M derived: sum of 4 quarters · filed 2022-05-09 | |||
| 2020-12-31 | -$12.94M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$20.98M derived: sum of 2 quarters · filed 2022-02-28 | -$880.66K 10-K/A · filed 2021-05-21 | -$700.83K 10-K · filed 2021-03-11 | -$45.25M derived: sum of 3 quarters · filed 2022-02-28 | -$36.53M 10-K · filed 2022-02-28 | ||
| 2020-09-30 | -$8.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$489.26K 10-Q · filed 2020-11-16 | -$32.31M derived: sum of 2 quarters · filed 2021-11-10 | -$23.59M 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | -$24.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$15.55M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $8.72M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |